Gosselies, Belgium – iTeos Therapeutics
SA, a biotechnology company developing novel cancer immunotherapies, today
announced the completion of an oversubscribed $75 million (€64 million) Series
B financing led by MPM Capital, with participation from additional new
investors HBM Partners, 6 Dimensions Capital and Curative Ventures. All
existing investors also participated in this financing round including Fund +,
VIVES II and SRIW, as well as SFPI. Read the official press release here.